Kestra Advisory Services’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-28,636
Closed -$270K – 3508
2026
Q2
$270K Buy
+28,636
New +$257K ﹤0.01% 2860
2022
Q2
– Sell
-8,946
Closed -$659K – 2214
2022
Q1
$659K Sell
8,946
-4,585
-34% -$409K 0.01% 1133
2021
Q4
$1.94M Buy
13,531
+658
+5% +$113K 0.02% 692
2021
Q3
$2.67M Buy
12,873
+3,273
+34% +$721K 0.03% 595
2021
Q2
$2.04M Buy
9,600
+5,831
+155% +$1.07M 0.02% 644
2021
Q1
$683K Buy
3,769
+760
+25% +$151K 0.01% 1043
2020
Q4
$358K Buy
+3,009
New +$320K ﹤0.01% 1373

Other funds holding NVAX

Kestra Advisory Services's NVAX Position: Q3 2026 in Review

Kestra Advisory Services sold out of Novavax (NVAX) in Q3 2026, closing a stake of 28,636 shares — an estimated $270K sold.

Kestra Advisory Services first reported a position in NVAX in Q4 2020 and held it in 7 quarters. The position peaked at $2.67M in Q3 2021. 262 funds tracked by Wall St. Rank hold NVAX as of Q3 2026.

  • Kestra Advisory Services reported no remaining Novavax position as of Q3 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 28,636 Novavax shares in Q3 2026, an estimated $270K.
  • Kestra Advisory Services first reported a position in Novavax in Q4 2020 and held it in 7 quarters.
  • Kestra Advisory Services's Novavax position peaked at $2.67M in Q3 2021.
  • 262 funds tracked by Wall St. Rank held Novavax as of Q3 2026.

Based on Kestra Advisory Services's 13F filing for Q3 2026, filed 2 Nov 2026.